Stop denying facts. If pharma companies want to improve outcomes and maintain long-term treatment persistence, they need to become active partners in the patient journey.

The Reality: Starting Therapy Is Easy Compared to Staying on It

Many patients begin GLP-1 therapy with high expectations. They see dramatic weight-loss stories on social media and hear glowing testimonials from friends and celebrities. What they don’t always hear about are the challenges.

Patients will experience nausea, constipation, fatigue, gastrointestinal discomfort, or plateaus in weight loss. Some become discouraged when results don’t happen as quickly as they expected. Others struggle to navigate insurance coverage or rising out-of-pocket costs. When these obstacles occur, many patients simply stop treatment.

Unfortunately, physicians often have limited time to provide the ongoing coaching and education patients need to stay engaged. This creates an opportunity for pharma companies to help.

Give Physicians Better Patient Education Tools

Most physicians don’t have the time to explain every aspect of the patient journey during a brief office visit. Pharma can help by creating practical educational materials that physicians can easily share. These resources should explain:

• What patients should realistically expect during the first few months of therapy
• Common side effects and how they may be managed
• The importance of lifestyle modifications
• Why treatment persistence matters
• What to do if weight loss slows or plateaus

The goal should not be promotion. The goal should be education.

Well-informed patients are more likely to remain engaged in their treatment plans.

Create Ongoing Patient Support Programs

Many patient support programs focus heavily on access and reimbursement assistance. While those services are important, GLP-1 patients often need much more. Pharma companies should consider providing:

• Personalized treatment reminders
• Digital coaching platforms
• Nutrition education
• Exercise guidance
• Progress tracking tools
• Access to nurse educators
• Behavioral support resources

Patients who feel supported are more likely to stay on therapy than those who feel isolated and overwhelmed.

Help Patients Set Realistic Expectations

One of the biggest threats to treatment persistence is unrealistic expectations. Social media has created a perception that everyone who takes a GLP-1 drug experiences rapid and dramatic weight loss. The reality is far more complex.

Patients respond differently. Some lose weight quickly. Others lose weight more gradually. Some encounter side effects that require adjustments. Pharma should work with physicians to provide balanced information about what success looks like over time. Managing expectations may not generate headlines, but it can significantly improve adherence.

Use Digital Tools to Monitor Patient Engagement

Pharma companies have invested billions in digital marketing. Now they should invest more heavily in digital patient support.

Secure mobile apps, patient portals, educational content hubs, and symptom-tracking tools can help patients stay connected to their treatment journey. These tools can also help identify when patients may be at risk of discontinuing therapy. A patient who stops opening an app, stops logging progress, or stops refilling prescriptions may need additional support before they abandon treatment altogether.

Listen to Patients Instead of Assuming What They Need

One of pharma’s biggest weaknesses has always been its assumption that it understands patients. GLP-1 therapy presents an opportunity to change that. Companies should be conducting ongoing social listening, patient advisory boards, online community monitoring, and qualitative research to understand what patients are experiencing in the real world. What side effects are causing concern? What barriers are preventing adherence? What misconceptions are spreading online? What support resources do patients actually find useful?

The answers to these questions can help companies design more effective support programs and educational initiatives.

Think Beyond the Prescription

The GLP-1 market is likely to remain one of the most competitive therapeutic categories in healthcare for years to come. Clinical efficacy will always matter. But in a crowded marketplace, patient experience may become just as important.

The companies that succeed won’t simply be the ones that develop effective medications. They will be the ones that help patients stay on therapy, achieve better outcomes, and navigate the challenges that come with long-term treatment. For GLP-1 drugs, the prescription should be viewed as the beginning of the relationship—not the end of it.

Pharma can no longer afford to prescribe and forget.

What About the “We’re A Regulated Industry”

Some of these initiatives can pose FDA regulatory risk if they’re not carefully designed. The key distinction is whether the activity is genuinely patient support and education or becomes promotional in ways that make efficacy claims, minimize risks, or encourage inappropriate use.

Here are a few areas where pharma companies need to be careful:

Patient Support Programs

Generally, these are low-risk if they focus on adherence, administration instructions, reimbursement support, and disease education.

The risk arises when support programs start making claims such as:

• “You’ll lose X pounds.”
• “Most patients achieve dramatic results.”
• “Stay on treatment, and you’ll reach your goal weight.”

Those types of messages could be viewed as promotional claims that require adequate support and balanced risk information.

Mobile Apps and Digital Tools

Apps can be useful, but pharma must avoid creating experiences that continuously reinforce benefits while ignoring risks. For example:

• Weight-loss trackers that celebrate every pound lost may be viewed differently than neutral tracking tools.
• Push notifications that emphasize benefits without including risk information could attract regulatory scrutiny.

Educational Content

This is probably the safest area if handled properly. Companies can help physicians explain:

• How the drug works
• Common side effects
• Importance of follow-up visits
• Lifestyle changes that complement treatment
• What patients should discuss with their healthcare provider

The FDA generally supports truthful, non-misleading educational information.

Nurse Educators and Coaching

This area requires significant training and oversight. The FDA has historically scrutinized interactions where company-sponsored nurses or educators appear to provide medical advice, recommend off-label uses, or influence treatment decisions. Programs should focus on education and support, not treatment recommendations.

Social Listening

Monitoring patient conversations is relatively low risk. However, if a company actively participates in discussions, responds to treatment questions, or amplifies patient success stories, it may incur additional promotional and adverse event reporting obligations.

The Biggest Risk: Making Persistence the Goal

This is where many companies can get into trouble. A company cannot simply say, “Stay on our GLP-1 no matter what.” The message must always be framed around appropriate use under physician supervision.

A better approach is:

“Patients should work with their healthcare provider to determine whether continuing therapy is appropriate and discuss any concerns or side effects.”

That keeps the physician at the center of treatment decisions.

The Case for Limiting Coverage

From an insurer’s perspective, the economics are becoming difficult to ignore. Many GLP-1 medications can cost more than $1,000 per month. When thousands of members are taking these drugs, annual spending can quickly reach tens or even hundreds of millions of dollars.

At the same time, studies have shown that a significant number of patients discontinue treatment within the first year. Research published in JAMA Network Open found that more than one-third of GLP-1 users stopped therapy within 12 months. Among patients using the drugs primarily for obesity, discontinuation rates exceeded 50%.

This creates a troubling scenario for payers. If a patient loses weight while taking a GLP-1 but regains most or all of it after stopping treatment, insurers may view the investment as producing only temporary benefits. Unlike a short course of antibiotics, obesity treatment often requires long-term or even lifelong therapy to maintain results.

Employers are increasingly asking a difficult question: Why should we continue paying thousands of dollars per patient each year if many patients won’t remain on treatment long enough to achieve lasting benefits? For organizations struggling with rising healthcare costs, limiting coverage may seem like a financially responsible decision.

The Case Against Limiting Coverage

The problem with this argument is that it may misunderstand the nature of obesity itself. Most physicians now recognize obesity as a chronic disease, similar to hypertension or diabetes. We don’t stop covering blood pressure medications because a patient’s blood pressure rises after discontinuing therapy. We don’t stop covering diabetes medications because blood sugar levels increase when treatment ends.

So why should obesity medications be treated differently? Many patients regain weight after discontinuing GLP-1 therapy because the underlying biological drivers of obesity have not disappeared. Hunger signals return. Metabolism adapts. Old eating behaviors often resurface.

In many cases, weight regain is not evidence that the drug failed. It may actually demonstrate that the medication was working.

Limiting coverage may save money in the short term while increasing long-term healthcare costs associated with obesity-related complications, including diabetes, heart disease, sleep apnea, and joint disorders. The irony is that some insurers may be cutting off access to therapies that could help prevent even more expensive medical conditions down the road.

The Real Problem: Prescribe and Forget

Perhaps the most important issue is one that neither insurers nor pharmaceutical companies discuss enough. Too often, patients are prescribed a GLP-1 and sent on their way. Many patients experience side effects such as nausea, vomiting, gastrointestinal discomfort, and fatigue. Others struggle to adjust their eating habits, maintain adequate protein intake, or incorporate physical activity into their routine.

Without support, some patients simply quit. This raises an uncomfortable question: Are high discontinuation rates really the patient’s fault?

Or is the healthcare system failing to provide the ongoing support necessary for long-term success? Drug manufacturers have invested billions in developing and marketing GLP-1 therapies. But helping patients stay on treatment may be just as important as convincing physicians to prescribe the drugs in the first place.

Pharma companies, healthcare providers, and payers should be working together to improve persistence through:

• Patient education programs
• Side effect management support
• Nutrition counseling
• Behavioral coaching
• Regular follow-up visits
• Digital engagement tools
• Adherence monitoring programs

If patients receive better support, discontinuation rates may fall and outcomes may improve.

A Middle Ground May Be Needed

Rather than simply expanding or restricting coverage, employers and insurers may need to adopt a more balanced approach. Coverage decisions could be tied to demonstrated engagement in comprehensive obesity management programs. Patients receiving nutritional counseling, regular physician follow-up, and lifestyle support may be more likely to remain on therapy and achieve sustainable results.

At the same time, pharma companies need to recognize that prescribing a medication is only the first step. Long-term success requires helping patients navigate side effects, maintain motivation, and understand that obesity management is often a lifelong journey.

Employers and insurers have legitimate concerns about the rapidly growing costs of GLP-1 medications and the high rates of treatment discontinuation. But limiting coverage may address the symptom rather than the underlying problem.

The real issue may not be that GLP-1 drugs don’t work. It may be that too many patients are being prescribed these medications without the support systems necessary to stay on them.

If obesity is truly a chronic disease, then healthcare stakeholders must stop thinking about GLP-1s as short-term weight loss solutions and start treating them as part of a long-term disease management strategy. The future of GLP-1 coverage may ultimately depend on a simple question:

Can the healthcare system do a better job helping patients stay on therapy long enough to realize the full benefits? Until that question is answered, the debate over coverage restrictions is unlikely to disappear.

Keywords: GLP-1 coverage, weight loss drugs, obesity treatment, GLP-1 discontinuation, healthcare costs, employer healthcare benefits, insurance coverage, Wegovy, Ozempic, obesity management

The biggest shift in healthcare occurred when pharma companies became increasingly accountable to investors. Publicly traded companies face relentless pressure to deliver quarterly growth. Investors expect rising revenue, expanding profit margins, and consistent earnings performance. CEOs who fail to meet expectations often face falling stock prices, activist investors, or even replacement.

As a result, pharma executives spend considerable time balancing two responsibilities:

• Developing medicines that improve lives
• Delivering financial returns to shareholders

When these goals conflict, financial performance often wins.

Drug Development Became More Expensive

Pharma executives frequently point out that developing a new drug is extraordinarily expensive. Research failures are common, and there are too many me-too drugs. Thousands of compounds may be tested before one reaches the market. Clinical trials have become larger, longer, and more complex. Regulatory requirements continue to expand, and turmoil at the FDA adds to approval delays.

The Patent Clock Creates Urgency

Patents are both a blessing and a curse for pharma companies. A company may spend a decade or more developing a medicine, but once approved, it has a limited period of market exclusivity before generic competition arrives. When generics enter the market, revenue can collapse almost overnight. This reality encourages companies to extract as much value as possible during the exclusivity period, often leading to aggressive pricing strategies.

The Rise of Blockbuster Thinking

Years ago, pharma companies often maintained broader portfolios of products with moderate sales. Today, many firms depend heavily on a handful of blockbuster drugs generating billions of dollars annually. The success or failure of a few products can significantly impact company performance.

This creates a culture in which companies increasingly focus their resources on therapies with the greatest commercial potential rather than necessarily on those with the greatest public health need. That is one reason why there are often more investments in common chronic diseases than rare conditions affecting smaller patient populations.

Mergers and Acquisitions Changed the Industry

Over the past several decades, the pharma industry has consolidated dramatically. Large companies have acquired competitors, biotechnology firms, and promising drug pipelines. These deals are usually justified by promises of greater efficiency and shareholder value. However, mergers often bring intense pressure to cut costs, improve margins, and justify acquisition premiums. Financial performance becomes even more important because the acquiring company must demonstrate that the deal was worthwhile.

Marketing Became a Strategic Weapon

Pharma companies today spend enormous sums on promotion, market access, payer negotiations, and commercialization. In many organizations, commercial considerations influence decisions much earlier in the development process than they did decades ago. Questions such as:

• Will insurers cover this drug?
• Can it achieve blockbuster status?
• How large is the patient population?
• What price can the market bear?

These often become central considerations alongside scientific merit.

Hiring People Who Only Know Spreadsheet Marketing

This is perhaps the biggest change I have witnessed. Pharma has hired a lot of people with MBAs, but they’re used to using spreadsheets to quantify everything. Patients don’t fit in a spreadsheet, and seeing them as just numbers distances patient marketing and makes it ineffective.

At the same time, too many pharma companies are getting rid of older employees under the guise of “cultural fit”. There is a hell of a lot of experienced pharma marketing people out there, and smaller biotechs seem to be gobbling them up because they need the experience.

The Healthcare System Rewards Revenue

It is important to recognize that pharma companies operate within a broader healthcare system that often rewards financial performance. Investors reward growth. Analysts reward growth. Executives are compensated based on growth. The system is designed to encourage companies to maximize shareholder value. Critics argue that this structure inevitably pushes healthcare companies toward decisions that favor profitability over affordability.

The Public’s Frustration Is Understandable

Many patients do not object to pharmaceutical companies making profits. After all, profits fund research, innovation, manufacturing, and future treatments. What frustrates many people is the perception that there is no limit. When patients struggle to afford life-saving medicines while pharmaceutical companies report billions in profits and conduct large stock buybacks, it creates a credibility problem. Patients begin to wonder whether the industry’s primary customer is the patient—or the shareholder.

The Future Challenge

The challenge facing Big Pharma is not choosing between profits and patients. Successful companies need both. The real challenge is maintaining public trust while delivering financial returns. If patients believe they are viewed primarily as revenue sources, trust erodes. And trust is one of the most valuable assets any healthcare company possesses.

The pharma industry has helped develop treatments that have extended and improved millions of lives. But the industry’s long-term success may depend on convincing patients, policymakers, and healthcare professionals that its commitment to improving health is at least as strong as its commitment to quarterly earnings.

That is a balancing act that will likely define Big Pharma’s future for decades to come.

Why? The answer has less to do with technology and more to do with trust, authenticity, and how people actually make healthcare decisions.

Health Decisions Are Emotional, Not Corporate

Pharma companies design product websites primarily to satisfy regulatory, legal, and promotional requirements. Patients, however, are looking for something very different. They want answers to questions such as:

• What does treatment really feel like?
• How bad are the side effects?
• Will I still be able to work?
• What happens if the drug doesn’t work?
• How did other patients handle this?

Most branded websites cannot answer those questions directly. Patients know they are viewing information created by the company selling the product. Even when the information is accurate and balanced, many visitors assume they are only seeing part of the story.

Research continues to show that trust is becoming one of the most important factors influencing healthcare decisions. The latest Edelman Trust and Health report found that influence over health decisions increasingly depends on who people trust, not simply who has medical expertise. Competing sources of health information now include peers, online communities, influencers, and AI-powered tools.

Patients Want People, Not Marketing

The internet has fundamentally changed how patients evaluate treatments. A Pew Research study found that Americans typically gather health information from multiple sources rather than relying on a single authority. Nearly three-quarters report using three or more information sources when making health-related decisions. That means a patient who visits a pharma website is likely also reading:

• Reddit discussions
• Facebook support groups
• Patient forums
• YouTube videos
• Health influencers
• AI-generated summaries
• News coverage

Patients are triangulating information. They don’t want a single corporate voice. They want a collection of perspectives that helps them feel confident in their decision.

Social Media Provides Something Pharma Can’t

What social media lacks in scientific rigor, it often makes up for in authenticity. Patients can hear directly from someone living with the same disease, experiencing the same symptoms, and taking the same medication.

According to KFF, 55% of adults say they use social media for health information and advice at least occasionally. Younger adults are even more likely to do so. Pew recently found that 36% of Americans get health information from social media, while 40% say they obtain health and wellness information from influencers or podcasts. Among adults under 50, that figure rises to about half. Patients are clearly willing to trade some degree of authority for relatability.

What Patients Are Saying Online

A quick look at healthcare discussions on Reddit reveals a recurring theme: skepticism toward institutions and a desire for unfiltered experiences. One Reddit user discussing pharma companies wrote:

“Healthcare is complex, expensive and everyone needs it.”

Another discussion about perceptions of pharmaceutical influence highlighted how distrust often exists even when people acknowledge the science behind medicines. The specific comments vary, but the underlying message is consistent: Patients want transparency. They want to hear from people who have “been there.” They want real experiences more than polished messaging. Unfortunately, that is precisely what most pharmaceutical product websites struggle to provide.

The Rise of Community-Based Healthcare Information

Researchers studying online health behavior have found that patients increasingly seek information in social environments. Earlier Pew research found that the pursuit of health information is highly social, with many people discussing what they find online with family members, friends, and fellow patients.

Recent research on self-diagnosis communities found that people often turn to platforms such as Reddit and Quora for convenience, rapid responses, community support, and anonymity. Distrust of traditional healthcare sources was also identified as a key factor.

This helps explain why a Reddit thread with hundreds of patient comments can sometimes attract more engagement than a professionally designed brand website costing millions of dollars.

Pharma Websites Were Built for Compliance, Not Conversations

Most pharmaceutical product websites were not designed around patient behavior. They were designed around legal review processes. As a result, many websites:

• Speak in corporate language.
• Focus on approved claims.
• Avoid nuance.
• Offer little opportunity for interaction.
• Present information in ways that feel promotional.

Meanwhile, patients are consuming short videos, patient stories, discussion forums, and conversational AI tools. The experience gap is enormous.

What Pharma Should Do Instead

This does not mean pharma product websites are obsolete. They remain essential sources of approved medical information. However, they can no longer be the center of the patient journey. Instead, pharma should think about product websites as one component within a broader ecosystem that includes:

• Social listening
• Patient communities
• Disease education content
• Healthcare professional engagement
• Search optimization
• Influencer monitoring
• AI discoverability

Most importantly, pharma companies need to spend more time understanding what patients are actually discussing online rather than assuming they will find the answers on a branded website.

Online health seekers aren’t avoiding pharma product websites because they dislike information. They’re avoiding them because they are looking for something more valuable than information. They’re looking for trust. They want real-world experiences, authentic conversations, community validation, and answers to questions that corporate websites often cannot address.

Until pharma companies recognize that healthcare decisions are influenced as much by human experiences as by clinical data, patients will continue to look elsewhere for guidance. And increasingly, “elsewhere” is not a product website.

Supporters of work requirements argue that able-bodied adults should be employed in exchange for receiving government benefits. On the surface, that may sound reasonable. Most Americans support the idea that people who can work should contribute to society. The problem is that healthcare isn’t a reward for employment. It’s healthcare.

Cancer doesn’t care whether you have a job. Neither does multiple sclerosis, heart disease, kidney failure, or any number of serious medical conditions. Yet work requirements create a system where people battling life-threatening illnesses can find themselves buried under paperwork, reporting requirements, and bureaucratic hurdles at precisely the moment they should be focusing on getting well.

Even when exemptions exist for people with serious illnesses, the reality is far messier than policymakers often admit. Patients are often required to prove they qualify for exemptions. Documentation can be delayed. Administrative errors occur. Eligibility reviews can take weeks or months.

Cancer patients know all too well that treatment schedules don’t wait for government paperwork. Someone undergoing chemotherapy may be physically unable to maintain a full-time job. Fatigue, nausea, infections, and frequent medical appointments can make employment difficult or impossible. Yet these same patients often need health insurance the most because cancer treatment can cost hundreds of thousands of dollars.

The irony is hard to miss. A person healthy enough to work may not need extensive medical care. A person too sick to work often requires the most expensive care imaginable. Yet work requirements can place the greatest burden on those least able to navigate them.

Supporters of these policies often talk about reducing dependency on government programs. But cancer patients are not choosing dependency. Nobody wakes up one morning and decides they would rather spend their days in infusion centers, radiation suites, and oncology clinics than earning a paycheck.

Illness is not a lifestyle choice. The broader question is what Medicaid is supposed to accomplish. Is it a healthcare program designed to ensure vulnerable Americans receive medical treatment? Or is it a workforce incentive program that conditions access to healthcare on employment status?

Those are two very different objectives. If Medicaid’s primary purpose is healthcare, then barriers that cause eligible patients to lose coverage deserve scrutiny. Numerous studies of work requirement programs have shown that many coverage losses occur not because people refuse to work, but because they fail to complete reporting requirements or navigate administrative systems.

When cancer treatment is interrupted because insurance coverage is lost, the consequences can be devastating. Delayed treatments can worsen outcomes. Missed appointments can allow diseases to progress. Financial stress can compound an already overwhelming diagnosis.

Healthcare policy should be judged by what happens to real patients, not by political talking points. The next time policymakers discuss Medicaid work requirements, they should ask themselves a simple question:

Should a person fighting cancer be worrying about surviving their disease—or proving to a government agency that they worked enough hours this month to deserve treatment? For many Americans, the answer seems obvious. Healthcare should be based on medical need, not the ability to clock in.

Wall Street Is Pricing a Perfect Scenario

Much of the bullishness surrounding GLP-1 drugs assumes a perfect chain of events. Millions of patients start therapy. Most stay on therapy indefinitely. Insurers continue paying for treatment. Governments expand coverage. Employers absorb rising healthcare costs. And new competitors fail to significantly disrupt pricing.

That’s a wonderful model for a spreadsheet. It’s a much harder model to sustain in the real world. Healthcare rarely operates according to investor presentations.

The Payer Pushback Has Already Started

One of the biggest risks to the GLP-1 growth narrative isn’t clinical. It’s financial and based on the “real world”. Weight loss drugs are expensive, and over 50% of patients are discontinuing due to side effects.

As demand grows, employers and health plans are discovering that covering obesity medications for large populations can add billions of dollars to healthcare spending. Many insurers have already imposed restrictions, tightened prior-authorization requirements, or declined coverage altogether, and patients are saying “enough” of the side effects.

The other question is “Why cover a drug where the majority of patients are going to regain their weight or discontinue?”

The issue isn’t whether these drugs work. The issue is whether the healthcare system can afford to provide them to everyone who needs them and whether patients want a drug they have to stay on for life.

That’s a very different conversation.

Every dollar spent on obesity medications is a dollar not spent elsewhere. Eventually, payers begin asking difficult questions about return on investment, long-term outcomes, budget impact, and living with nasty side effects that affect the quality of life. The more hyped these drugs become, the greater the pressure on insurers to limit spending. Ironically, growing demand could create the very reimbursement barriers that slow future growth.

The Industry’s Dirty Little Secret: Patients Quit

Another issue receiving far less attention than prescription growth is what happens after patients start treatment. A significant number discontinue therapy. Some stop because of gastrointestinal side effects such as nausea, vomiting, diarrhea, or constipation. Others stop because insurance coverage changes. Some simply cannot justify the ongoing out-of-pocket expense.

Yet many Wall Street models appear to assume a level of patient persistence that may prove unrealistic over time. A prescription written today does not necessarily mean a patient will still be taking the drug next year.

For investors focused on lifetime customer value, that distinction matters. A lot.

The Weight Regain Problem Creates New Questions

The industry’s preferred narrative is that obesity is a chronic disease requiring chronic treatment. Clinically, that argument has merit. Commercially, it creates a challenge. Many patients are discovering that stopping therapy often leads to regaining some or much of the weight they lost. That means maintaining results may require years or even decades of treatment.

The question becomes whether patients, employers, insurers, and government programs are willing to pay for lifelong therapy on such a massive scale. The answer is far from certain. Wall Street often treats this as proof of recurring revenue. Payers may view it as proof of recurring costs. Those are not the same thing.

Lilly and Novo Understand What Investors May Not

None of this suggests that Lilly or Novo Nordisk are worried about the immediate future. Their obesity franchises will likely generate enormous revenue for years. But smart pharma companies do not build their futures around best-case scenarios. They prepare for competitive pressures. They prepare for reimbursement challenges. They prepare for changing patient behavior.

And they prepare for the possibility that today’s blockbuster market eventually matures. That is why both companies continue investing heavily in other therapeutic areas rather than acting as if obesity alone will fuel growth forever. Their actions suggest a level of caution that is often missing from Wall Street’s enthusiasm.

The Risk Isn’t That GLP-1s Fail

The risk isn’t that GLP-1 drugs stop working. The risk is that investors have convinced themselves that clinical success automatically translates into unlimited commercial success. Healthcare doesn’t work that way. Payers push back. Patients discontinue therapy. Governments scrutinize spending. Competitors emerge. Prices come under pressure.

The history of the pharma industry is filled with products that looked unstoppable until market realities intervened. GLP-1s may become one of the largest drug categories in history. But even the biggest pharmaceutical markets eventually encounter limits. Lilly and Novo appear to understand that.The question is whether Wall Street does.

Newly diagnosed cancer patients have a lot of questions:

• Am I going to die?
• How will this affect my family?
• What treatment options do I have?
• Can I afford it?
• Will I be able to work?
• What happens next?

At the same time, caregivers—spouses, children, parents, and friends—begin their own emotional journey. While the patient is trying to process the diagnosis, caregivers are often trying to remain strong while quietly dealing with fear, uncertainty, and overwhelming responsibility.

The Information Overload Problem

One of the greatest challenges facing newly diagnosed patients is information overload. During the first few days after diagnosis, patients are often asked to absorb complex medical information about tumor types, biomarkers, treatment options, side effects, clinical trials, and insurance coverage. Unfortunately, fear and anxiety make it difficult to process information.

Research has consistently shown that patients frequently forget much of what is discussed during medical appointments. Caregivers may remember more, but they are often overwhelmed as well. As a result, many patients turn to Google, YouTube, social media, online communities, and patient forums seeking answers.

While some of the information they find is helpful, much of it can be confusing, outdated, or inaccurate. Patients can quickly become overwhelmed by conflicting advice and frightening stories that may not apply to their situation.

The Emotional Journey Is Often Ignored

Healthcare systems are designed to diagnose and treat disease. Patients, however, are trying to manage something much bigger. They are dealing with uncertainty. Many patients report feeling isolated after diagnosis. Friends may not know what to say. Family members may avoid difficult conversations. Some patients worry about becoming a burden to loved ones.

Caregivers face similar challenges. They often become appointment coordinators, medication managers, transportation providers, advocates, and emotional support systems overnight. Yet caregiver support is frequently overlooked despite the critical role caregivers play in treatment adherence and patient outcomes.

Where Pharma Can Make a Difference

Pharma companies often focus their communications on clinical efficacy, safety profiles, and treatment outcomes. These are obviously important. However, patients need more than treatment information. They need guidance.

The reality is that many patients encounter a pharma brand long before they start treatment and continue interacting with it throughout their journey. This creates an opportunity for pharma to provide meaningful support that extends beyond product promotion.

Help Patients Understand What Comes Next

One of the greatest sources of anxiety is uncertainty. Patients want to know what to expect during testing, treatment initiation, side effect management, follow-up appointments, and ongoing care. Educational resources that explain the treatment journey in plain language can help reduce fear and improve confidence.

The goal should not be to overwhelm patients with information but to provide the right information at the right time.

Create Resources for Caregivers

Caregivers are often the invisible members of the care team. Pharma can help by creating educational materials specifically designed for caregivers, addressing issues such as:

• Managing appointments
• Supporting medication adherence
• Recognizing side effects
• Communicating with healthcare providers
• Managing caregiver stress and burnout

Supporting caregivers ultimately supports patients.

Improve Digital Experiences

Many oncology websites are designed around the product rather than the patient experience. Patients frequently arrive with questions that have little to do with clinical endpoints.

They want answers to practical concerns:

• What should I ask my doctor?
• How do I talk to my family about my diagnosis?
• What financial assistance programs are available?
• How can I connect with other patients?
• What should I expect during treatment?

Providing easy-to-find answers to these questions can create a more valuable and supportive experience. They could even develop an app for newly diagnosed cancer patients to help them manage their appointments and answer questions.

Connect Patients to Trusted Support Networks

Patients often benefit from connecting with advocacy organizations, support groups, nurse navigators, and financial assistance programs. Pharma companies can serve as trusted connectors by helping patients find credible resources rather than forcing them to search for help on their own.

Listen More Than You Talk

Perhaps the most important thing pharma can do is listen. Social listening, patient advisory boards, caregiver interviews, and patient community engagement can provide insights into what patients truly need throughout their journey. The challenges patients face are often emotional, logistical, and financial—not just clinical.

Understanding those realities can help companies develop programs and resources that genuinely improve the patient experience.

Remember the Human Being Behind the Diagnosis

Patients do not wake up thinking about mechanisms of action, progression-free survival curves, or clinical trial endpoints. They wake up wondering whether they will see their children grow up, attend a wedding, celebrate another anniversary, or simply feel normal again. Caregivers wonder how they can help someone they love navigate one of the most frightening experiences of their lives.

Cancer treatment will always begin with science. But helping patients through cancer requires empathy. The pharma companies that make the greatest impact will be those that remember there is a human being behind every diagnosis, a family behind every patient, and an opportunity to provide support that extends far beyond the medicine itself.

Across our industry, experienced professionals are being shown the door through layoffs, early retirement packages, and restructuring efforts. At the same time, many highly qualified candidates with decades of experience struggle to get interviews, let alone job offers.

The irony is hard to ignore. Pharma executives frequently talk about the importance of expertise, institutional knowledge, and strategic thinking. Yet many companies appear willing to discard precisely the people who possess those qualities.

Experience Matters

Pharma marketing, sales, market access, compliance, and medical affairs are not simple disciplines. They require years of experience navigating regulations, understanding healthcare systems, managing relationships with physicians, and learning from both successes and failures.

A marketer who has successfully launched multiple brands over twenty years brings more than technical knowledge. They bring judgment. Medical Laisons who worked on newly launched products understand what’s needed to communicate with medical proffesionals.

They understand how physicians actually make decisions. They know how patients behave in the real world. They recognize warning signs before a campaign goes off track. They have lived through market disruptions and understand that today’s “new” challenge often resembles a problem that appeared years earlier.

Unfortunately, many organizations seem to view experienced employees primarily as a cost rather than an asset.

The Cost-Cutting Trap

When layoffs occur, older workers are often among the highest-paid employees. From a spreadsheet perspective, eliminating a handful of senior professionals can create immediate savings. But what happens afterward?

Companies lose institutional memory. Teams lose mentors. Younger employees lose access to experienced leaders who can help them avoid costly mistakes. The financial savings may appear attractive in the short term, but the long-term consequences can be significant. Knowledge that took decades to acquire walks out the door and is often impossible to replace quickly.

The Myth That Younger Means Better

Many organizations seem to operate under the assumption that younger employees are naturally more innovative, more adaptable, or more digitally savvy. Reality is far more complicated.

Some of the most successful digital marketers in pharma have spent decades adapting to change. They have survived the rise of websites, search engines, social media, mobile devices, programmatic advertising, artificial intelligence, and countless other technological shifts. Adaptability is not determined by age. It is determined by mindset.

Likewise, innovation does not belong exclusively to younger workers. Some of the industry’s most creative ideas come from people with enough experience to recognize patterns others miss.

A Dangerous Message

When companies routinely eliminate experienced workers or refuse to hire them, they send a message throughout the organization. Employees begin to wonder whether loyalty matters. They start to ask themselves why they should invest years in building expertise if they may be viewed as expendable once they reach a certain age or salary level.

This can damage morale, reduce engagement, and make it harder to retain top talent at every career stage.

Pharma Needs Experience More Than Ever

The industry is entering a period of extraordinary change. Artificial intelligence is transforming marketing and drug development. Patients are increasingly using digital channels to educate themselves. Healthcare economics are becoming more complex.

These challenges require fresh thinking. But they also require experienced professionals who understand the industry’s history, regulations, and realities.

The solution is not choosing between younger and older employees. The strongest organizations combine the energy and new perspectives of younger professionals with the wisdom and judgment of experienced veterans.

Pharma leaders often talk about making evidence-based decisions. If that’s truly the goal, they should examine the evidence surrounding age diversity in the workforce. Experience is not a liability. It is not something to be discarded when budgets tighten. It is a competitive advantage.

An industry built on science should recognize that. Instead, too many pharmaceutical companies appear to be treating experience as a cost center rather than an asset. That may help quarterly earnings. But it could also be one of the reasons the industry continues to struggle with innovation, employee engagement, and strategic execution.

Pharma doesn’t have an experience problem. It has an ageism problem.

Healthcare insurers often defend practices such as prior authorization and step therapy by claiming they help control costs and ensure appropriate care. Cost management is important. Nobody disputes that healthcare spending must be addressed. But somewhere along the way, the balance shifted.

Instead of serving as a safeguard, many insurance company approval processes have become barriers that delay, restrict, or outright deny medically necessary treatments recommended by physicians. What’s particularly frustrating is that these restrictions often occur while major health insurers report billions of dollars in profits.

Patients are frequently told that a treatment isn’t covered because it’s too costly, yet the same insurers continue to post strong earnings, increase executive compensation, and reward shareholders. It’s difficult for patients and physicians to understand why financial performance seems to take precedence over medical judgment.

The people making treatment recommendations are not strangers to the patient. Physicians spend years in training. They review medical histories, evaluate symptoms, analyze test results, and understand each individual’s unique circumstances. Insurance reviewers often never meet the patient. Yet they can delay treatment for weeks or months through administrative hurdles, forcing patients to try less effective therapies first or navigate endless appeals.

The consequences are not merely inconvenient. Delays can allow diseases to progress. Patients can suffer unnecessary pain. Some may later require more intensive and expensive interventions because the original treatment recommendation was postponed.

Ironically, many of these delays may increase healthcare costs rather than reduce them.

The physician-patient relationship should be the foundation of medical decision-making. Insurance companies certainly have a role in managing benefits and negotiating costs, but they should not have the authority to routinely substitute their judgment for that of treating physicians.

If insurers believe a recommendation is inappropriate, there should be a rapid, transparent review process involving qualified specialists in the relevant field. Patients should also have clear and accessible avenues to appeal decisions without having to become full-time advocates for their own care. Most importantly, the default position should be trust in the physician who knows the patient—not skepticism.

Healthcare is not a commodity like buying a television or choosing a cellphone plan. For many patients, treatment decisions can determine quality of life, long-term health outcomes, and sometimes survival itself. When insurers report record profits while simultaneously denying or delaying physician-recommended treatments, it is reasonable for patients to wonder whose interests are truly being served.

The healthcare system works best when medical decisions are guided by clinical evidence and the expertise of healthcare professionals—not by financial targets. Patients deserve timely access to the treatments their physicians believe are appropriate. Doctors deserve the ability to practice medicine without unnecessary interference. And insurers should be held accountable when cost containment impedes patient care.

At the end of the day, healthcare should be about helping people get better—not protecting profit margins.

In today’s world, TV advertising may be one of the least efficient ways to influence treatment decisions. Think about how people make healthcare decisions now. Most patients don’t see a commercial and immediately call their doctor. Instead, they pull out their phone. They search Google. They visit health websites. They watch videos. They join patient groups on Facebook or Reddit. They read reviews and stories from people living with the same condition. So why is pharma so entrenched in TV ads?

Many pharma executives built their careers during the golden age of DTC television advertising. For decades, success was measured by television reach, frequency, and awareness. Entire marketing organizations were built around TV campaigns. When you’ve spent 30 years seeing something work, it’s difficult to abandon it. Organizations often continue investing in familiar channels long after consumer behavior has changed. So should TV ads be banned to lower drug prices? No.

Unfortunetly one of the biggest misconceptions in healthcare policy is the belief that banning pharma advertising will somehow lower drug prices. It won’t.

Drug prices are not determined by advertising budgets.

The price of a prescription drug is influenced by years of research and development, patent protections, manufacturing costs, regulatory requirements, distribution systems, rebate negotiations, pharmacy benefit managers, insurers, and market competition. Advertising represents only a small piece of a much larger economic puzzle.

Even if pharma companies eliminated every television commercial tomorrow, there is no reason to believe those savings would be passed directly to patients.

Companies don’t typically lower prices simply because one expense category declines. More often, those resources are redirected into other areas of the business, whether that’s digital marketing, sales efforts, research programs, acquisitions, or shareholder returns. That’s why proposals to restrict DTC advertising often feel more symbolic than substantive.

Will fewer commercials mean fewer people asking their doctors about expensive brand-name drugs? Probably. Will it reduce some unnecessary demand? Possibly. Will it lower what patients pay at the pharmacy counter? Probably not.

The uncomfortable truth is that America’s drug pricing problem is far more complicated than what appears between commercial breaks during a football game.

If policymakers truly want to reduce prescription drug costs, they need to focus on the factors that actually drive pricing. That means addressing patent strategies, promoting competition, examining the role of pharmacy benefit managers, improving pricing transparency, and continuing to explore ways to negotiate costs more effectively.

Those are difficult conversations. Banning TV commercials is much easier. But easy solutions are not always effective solutions. Pharmal companies should probably rethink whether spending billions on television advertising still makes sense in a world where patients increasingly make healthcare decisions online.

At the same time, critics should stop pretending that restricting DTC advertising is some magic bullet for lowering drug prices. The two issues may be related, but they are not the same. And confusing them risks distracting us from the real causes of high healthcare costs.